Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis
BackgroundLebrikizumab, an IL-13 immunomodulator, has shown recommendable effectiveness and safety in clinical studies for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults.ObjectiveTo evaluate the efficacy and safety of lebrikizumab in the treatment of moderate-to...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2024-11-01
|
| Sarja: | Frontiers in Pharmacology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1429709/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|